
New RSV shot not available to Alberta newborns as virus season ramps up
CBC
Some Alberta doctors are calling on the provincial government to make an injection designed to protect newborns from severe RSV available for free to all babies.
Nirsevimab, a monoclonal antibody product, was approved by Health Canada last year.
The shot contains lab-made proteins that act like those created by the body's own immune system. While it is administered prior to exposure, it is not a vaccine.
Ontario and Quebec recently announced the launch of full-fledged provincially funded programs for infants. Nunavut, the Northwest Territories and Yukon are also offering coverage.
But the preventative medication, which goes by the brand name Beyfortus, is not yet available in Alberta.
"Here in Alberta I feel like we are at a disadvantage compared to other provinces," said Dr. Fiona Mattatall, a Calgary-based obstetrician.
She'd like to see the provincial government provide the shot — for free — to all newborns.
"We have heard nothing from the Ministry of Health or public health to help us know what to do as obstetricians in guiding our patients in this RSV season."
In response to an inquiry from CBC News, Alberta Health confirmed the injections are not available to Alberta newborns.
"For the 2024-25 season, AHS is continuing to work to secure nirsevimab (Beyfortus) for Alberta infants, but the manufacturer has been unable to guarantee supply," a spokesperson said in an email.
The statement did not say how many doses the province is trying to obtain or whether universal coverage would be offered to infants. The new shot is not available for purchase on the private market, according to the province.
Health Canada also recently approved Abrysvo, a vaccine given during pregnancies to pass along RSV immunity to newborns.
And while there is supply through pharmacies, pregnant Albertans have to pay out of pocket for the vaccine. Mattatal would like to see free, universal coverage for Abrysvo as another option for patients.
Alberta is continuing to provide an older monoclonal antibody shot to some high-risk babies, which is administered once a month for the duration of the RSV season.













